We demonstrate, for the first time, that the expression of PTK2B and LYN identify a patient subgroup within AML intermediate-risk patients with a better prognosis, whereas PTK2 expression (together with PTK2B or LYN underexpression) identifies patients with a poorer prognosis. The gene discussed is LYN; the disease is acute myeloid leukemia.